Clinical effect of intravenous thrombolysis with Alteplase combined with Clopidogrel and Aspirin treating acute ST segment elevation myocardial infarction
YANG Xia-tong1 CHEN Ke-quan2 SU Ning3 FENG Jing-tao4 TAN Zhi-xiong1 CHEN Yang1
1.Department of Emergency Internal Medicine,Central Hospital of Longhua District in Shenzhen City,Guangdong Province,Shenzhen 518110,China;
2.Department of Internal Medicine,the First Affiliated Hospital of Guangzhou Medical University,Guangdong Province,Guangzhou 510120,China;
3.Department of Internal Medicine,Central Hospital of Guangming New District in Shenzhen City,Guangdong Province,Shenzhen 518120,China;
4.Hunan Institute of Schistosomiasis Control,Hunan Province,Yueyang 414000,China
Abstract：Objective To observe the clinical effect of intravenous thrombolysis with Alteplase combined with Clopidogrel and Aspirin treating acute ST segment elevation myocardial infarction.Methods A total of 66 patients with acute ST-segment elevation myocardial infarction admitted into our hospital from January 2016 to January 2018 were selected.All patients were treated by intravenous thrombolysis with Alteplase combined with Clopidogrel and Aspirin.The patients were divided into the 6 h group(n=45)and＞6-12 h group(n=21)according to the time of onset.Coronary recanalization rate after treatment and APACHEⅡscore at 24 h after thrombolysis were compared in patients between the two groups.Results The coronary recanalization rate (59.09%)in the 6 h group was significantly higher than that in the＞6-12 h group(18.18%)(P＜0.05),and the APACHEⅡ score at 24 h after thrombolysis were significantly different between the two groups(P＜0.05).Conclusion intravenous thrombolysis with Alteplase combined with Clopidogrel and Aspirin treating acute ST segment elevation myocardial infarction is safe and effective treating acute ST segment elevation myocardial infarction,and the sooner thrombolysis is performed,the better the prognosis of patients.
Ibanez B，James S，Agewall S，et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].Kardiol Pol，2018，76（2）：229-313.
[3]
Aeyels D，Seys D，Sinnaeve PR，et al.Managing in-hospital quality improvement：an importance-performance analysis to set priorities for ST-elevation myocardial infarction care[J].Eur J Cardiovasc Nurs，2018.[Epub ahead of print]
Lnborg J，Vejlstrup N，Kelbeak H，et al.Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction[J].Eur Heart J，2012，33（12）：1491-1499.
[9]
De Francesco M，Ronco C，Wacinski PJ，et al.Economic impact of contras t-induced acute kidney injury associated with invasive cardiology：role of iso-osmolar contrast media in Germany，Italy，Poland，and Spain[J].J Med Econ，2016，19（2）：158-168.
[10]
Binbrek AS1，Rao NS，Al Khaja N，et al.Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction[J].Am J Cardiol，2009，104（8）：1035-1040.
Tsivgoulis G，Katsanos AH，Zand R，et al.Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke： a systematic review and meta-analysis[J].J Neurol，2017，264（6）：1227-1235.
[13]
Prech M，Bartela E，Janus M，et al.Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneouscoronaryintervention[J].CoronArteryDis，2016，27（7）：580-585.
[15]
Lam S，Tran T.Vorapaxar：a protease-activated receptor antagonist for the prevention of thrombotic events[J].Cardiol Rev，2015，23（5）：261-267.
京公网安备 11010502046607号